

AB-729, a GalNAc-siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection

E Gane,¹ E Berliba,² VJ Kim,³ J Holmes,⁴ Y-S Lim,⁵ S Strasser,⁶ W Sukeepaisarnjaroen,⁷ C Schwabe,¹ A Jucov,² ACH Lee,⁸ EP Thi,⁹ T Harasym,⁸ GR Pamulapati,⁸ P Wattamwar,⁸ J Kunta,⁸ M Sofia,⁸ H Sevinsky,⁸ K Gray,⁹ T Eley,⁹ G Picchio,⁹ KD Sims,⁹ MF Yuen⁹

¹Auckland Clinical Studies, New Zealand; ²Arenis Laboratory Medicine, Moldova; ³Seoul National University Hospital, South Korea; ⁴St. Vincent's Hospital, Melbourne, Australia; ⁵Asan Medical Center, Seoul, South Korea; ⁶Royal Prince Alfred Hospital, Sydney, Australia; ⁷Srinagarind Hospital, Khon Kaen, Thailand; ⁸Arbutus Biopharma, Warminster, PA, USA; ⁹Queen Mary Hospital, Hong Kong


BACKGROUND

- Chronic hepatitis B (CHB) can result in the development of cirrhosis, hepatocellular carcinoma, and progression to end-stage liver disease.^{1,2}
- Current therapies slow or prevent the development of HBV-related liver complications,^{3,4,5} but do not typically lead to a cure. Thus, there is an unmet medical need for new HBV therapies that have the potential to provide a functional cure for CHB.
- AB-729 is a subcutaneously administered single trigger GalNAc-conjugated RNA interference therapeutic candidate. The proprietary GalNAc liver targeting technology ensures high affinity and uptake into hepatocytes via the asialoglycoprotein receptor (ASGPr).
- In preclinical models, AB-729 reduced all HBV transcripts and antigens thereby inhibiting HBV replication,⁶ and was shown to have activity against all HBV genotypes in vitro.
- AB-729-001 is a 3-part study examining the safety and pharmacodynamics (PD) of AB-729 (Figure 1).
- Single doses of AB-729 (Cohorts A, B, C) and repeat dosing of AB-729 60 mg every 4 weeks (Q4W, Cohort E) in virologically-suppressed CHB subjects have been previously reported.⁷
- Here we report safety and PD through:
 - 24 weeks following a single dose of AB-729 90 mg in HBV DNA+ CHB subjects. In the absence of nucleos(t)ide analogue (NA) therapy (Cohort D)
 - 24 weeks with repeat dosing of AB-729 60 mg every 4 weeks (Q4W) in virologically-suppressed subjects (Cohort E)
 - 16 weeks with repeat dosing of AB-729 60 mg every 8 weeks (Q8W) in virologically-suppressed subjects (Cohort F).

AB-729-001 STUDY DESIGN

Figure 1. AB-729-001 Study Design

In Part 2, AB-729 was administered to subjects as single doses of 60 mg – 180 mg on Day 1. In Part 3, repeat doses of AB-729 60 mg or 90 mg were administered at varying dosing intervals for 20 weeks.



Q4W: every 4 weeks, Q8W: every 8 weeks, Q12W: every 12 weeks
*One subject removed from analysis due to spontaneous HBV flare prior to dosing (pre-dose Day 1 ALT elevated to 149 U/L from Screening value of 24 U/L, TDF initiated by investigator on Day 8), thus data presented are for N=5

Key Inclusion Criteria:

- All Cohorts: HBeAg positive or negative; HBsAg ≥ 250 IU/mL
- Virologically-suppressed Cohorts (A, B, C, E, F, I, J): HBV DNA $< \text{LLOQ}$, on stable NA treatment for ≥ 6 months
- HBV DNA+ Cohorts (D, G): HBV DNA ≥ 1000 IU/mL
- Single dose Cohorts (A, B, C, D): ALT/AST $\leq 5 \times \text{ULN}$
- Repeat dose Cohorts (E, F, G, I, J): ALT/AST $\leq 2 \times \text{ULN}$

RESULTS

Table 1. Baseline Characteristics

Baseline Measure	Cohort D 90 mg SD HBV DNA+ [N=5]	Cohort E 60 mg Q4W [N=7]	Cohort F 60 mg Q8W [N=7]
Age in years, mean (range)	43.6 (35–57)	45.1 (33–63)	44.0 (31–59)
Male gender, n (%)	3 (60%)	4 (57%)	4 (57%)
BMI mean (SD)	29.2 (5.42)	27.7 (5.01)	23.7 (2.17)
Race, n (%)			
Asian	0	1 (14%)	5 (71%)
White	4 (80%)	6 (86%)	1 (14%)
Black	0	0	1 (14%)
Other	1 (20%)	0	0
ALT (U/L) mean (SD)	31.6 (13.4)	22.4 (10.5)	23.4 (15.2)
HBV eAg, n (%)	5 (100%)	7 (100%)	6 (86%)
HBsAg (IU/mL) mean (range)	2336 (317–6,451)	5372 (584–11,761)	5354 (667–18,605)
HBV DNA (IU/mL) mean (range)	86,840 (1,220–360,560)	N/A	N/A

SD: single dose

RESULTS

Figure 2: Individual and mean change from baseline HBsAg (A) and HBV DNA (B) following a single dose of AB-729 90 mg in HBV DNA+ subjects (Cohort D)





Figure 3: Individual HBsAg, HBV DNA, and ALT following administration of a single dose of AB-729 90 mg in HBV DNA+ subjects (Cohort D)



*dotted horizontal line represents ALT ULN (43 U/L for females, 48 U/L for males)

Figure 5: Mean (SE) $\Delta \log_{10}$ HBsAg following repeat dosing of AB-729 60 mg Q4W (Cohort E) and Q8W (Cohort F)





Figure 4: Individual maximum HBV RNA decline within the first 12 weeks following administration of a single dose of AB-729 90 mg in HBV DNA+ subjects (Cohort D)



HBV RNA samples below the lower limit of quantitation (1.65 \log_{10} U/mL) or target not detected (#) assigned a value of 1.64 \log_{10} U/mL for the purpose of this assessment. Last available HBV RNA timepoint at Week 12 (a), Week 8 (b), and Week 10 (c)

Table 2. Safety Results

Subjects, n (%)	Cohort D (90 mg SD HBV DNA+) [N=5]	Cohort E (60 mg Q4W) [N=7]	Cohort F (60 mg Q8W) [N=7]	TOTAL [N=19]
Subjects with any TEAE	3 (60)	4 (57)	4 (57)	11 (58)
Subjects with related TEAEs (all Grade 1)	1 (20)	2 (29)	4 (57)	7 (37)
Most common related TEAEs (in ≥ 2 subjects):				
Injection site pain	0	0	2 (29)	2 (3) ^a
Injection site erythema	0	2 (29)	1 (14)	4 (6) ^a
Injection site bruising	1 (20)	2 (29)	0	3 (4) ^a
Laboratory Abnormalities (in ≥ 2 subjects):				
ALT elevation				
Grade 1	2 (40)	2 (29)	1 (14)	5 (26)
Grade 2 ^b	0	2 (29)	1 (14) ^c	3 (16)
AST elevation (Gr 1)	0	2 (29)	2 (29)	4 (21)
Sodium (low, Gr 1)	0	1 (14)	1 (14)	2 (11)

TEAE: treatment-emergent adverse event
Grading criteria based on Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1
^an, % is number of events out of 70 total AB-729 doses administered
^bGrade 2 ALT elevations were transient and all improved to Grade 1
^cSubject had history of pre-study Grade 1 ALT abnormalities

Table 3. Summary PD data for AB-729 60 mg administered every 4 weeks or every 8 weeks

Visit	AB-729 60 mg Q4W [Cohort E, N=7]	AB-729 60 mg Q8W [Cohort F, N=7]
Week 16	Mean (SE) $\Delta \log_{10}$ HBsAg: -1.44 (0.18) IU/mL 4/7 HBsAg < 100 IU/mL 4/7 $> 1.5 \log_{10}$ HBsAg decline	Mean (SE) $\Delta \log_{10}$ HBsAg: -1.39 (0.07) IU/mL 3/7 HBsAg < 100 IU/mL 3/7 $> 1.5 \log_{10}$ HBsAg decline
Week 24	Mean (SE) $\Delta \log_{10}$ HBsAg: -1.84 (0.16) IU/mL 5/7 HBsAg < 100 IU/mL 6/7 $> 1.5 \log_{10}$ HBsAg decline	not yet available

CONCLUSIONS

- In HBV DNA+ CHB subjects administered a single dose of AB-729 90 mg in the absence of NA therapy:
 - HBsAg remained suppressed in all subjects up to 24 weeks post-dose; however HBV DNA rebound was observed in some subjects post-Week 12.
 - HBV RNA declined in all subjects up to 12 weeks post-dose (the last time point available for HBV RNA), with 4/5 subjects reaching either undetectable or unquantifiable HBV RNA at some point.
 - ALT elevations were benign and did not appear to correlate with either HBsAg or HBV DNA profiles, including HBV DNA rebound.
 - These data continue to support AB-729 dosing in combination with other agents at intervals up to every 12 weeks.
- In virologically suppressed CHB subjects administered AB-729 60 mg every 4 weeks (Cohort E) or every 8 weeks (Cohort F):
 - Mean (SE) HBsAg declines were similar up to Week 16, providing further evidence that AB-729 can be dosed less frequently than every 4 weeks.
 - Mean HBsAg continued to decline through Week 24 following repeat dosing of AB-729 60 mg every 4 weeks.
 - 7/7 subjects have consented to participate in a treatment extension arm where they will continue to receive AB-729 for an additional 6 months.
 - Based on single dose PD data presented previously,⁷ the dosing interval of AB-729 60 mg was increased to every 12 weeks for the extension period.
- AB-729 was well tolerated after single doses in HBV DNA+ subjects and after multiple doses in virologically suppressed CHB subjects:
 - All TEAEs were Grade 1 excepting one case of unrelated COVID-19 with fever (Grade 2).
 - Transaminase elevations were modest and transient, none were symptomatic or were accompanied by bilirubin elevations or other clinically relevant laboratory changes and were not assessed as TEAEs.

REFERENCES

- Trépo C, Chan H and Lok A. Lancet, 2014.384.p.2053-2063.
- Yuen MF, et al. Nat Rev Dis Primers, 2018.4.p.18035.
- European Association for the Study of the Liver, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B infection. J Hepatol, 2017.67(2):370-398.
- Sarin SK, et al. Hepatol Int, 2016.10(1):p.1-98.
- Terrault N, et al. Hepatol, 2018.67(4):p.1560-1599.
- Lee ACH. EASL 2018.
- Yuen MF, et al. AASLD 2020.

ACKNOWLEDGEMENTS

Arbutus Biopharma thanks all participating subjects and their families, the investigators and site staff, Novotect, Covance, Maks Chernyakhovskyy, Deana Antonello, and the AB-729 Research and Clinical Development Teams.

CONTACT INFORMATION AND DISCLOSURES

- Heather Sevinsky, Senior Director, AB-729 Compound Development Lead and Clinical Pharmacology
- Arbutus Biopharma Inc., 701 Veterans Circle, Warminster, PA 18974
- Email: heavinsky@arbutusbio.com
- TEL: +1-267-420-3693
- Authors affiliated with Arbutus Biopharma are employees and may own company stock.
- www.arbutusbio.com